- Ferhati, Xhenti
- Jiménez-Moreno, Ester
- Hoyt, Emily A.
- Salluce, Giulia
- Cabeza-Cabrerizo, Mar
- Navo, Claudio D.
- Compañón, Ismael
- Akkapeddi, Padma
- Matos, Maria J.
- Salaverri, Noelia
- Garrido, Pablo
- Martínez, Alfredo
- Laserna, Víctor
- Murray, Thomas V.
- Jiménez-Osés, Gonzalo
- Ravn, Peter
- Bernardes, Gonçalo J. L.
- Corzana. Francisco
Antibody-drug conjugates (ADCs) are a class of targetedtherapeutics used to selectively kill cancer cells. It is important that theyremain intact in the bloodstream and release their payload in the targetcancer cell for maximum efficacy and minimum toxicity. The development ofeffective ADCs requires the study of factors that can alter the stability of thesetherapeutics at the atomic level. Here, we present a general strategy thatcombines synthesis, bioconjugation, linker technology, site-directed muta-genesis, and modeling to investigate the influence of the site andmicroenvironment of the trastuzumab antibody on the stability of theconjugation and linkers. Trastuzumab is widely used to produce targeted ADCs because it can target with high specificity a receptorthat is overexpressed in certain breast cancer cells (HER2). We show that the chemical environment of the conjugation site oftrastuzumab plays a key role in the stability of linkers featuring acid-sensitive groups such as acetals. More specifically, Lys-207,located near the reactive Cys-205 of a thiomab variant of the antibody, may act as an acid catalyst and promote the hydrolysis ofacetals. Mutation of Lys-207 into an alanine or using a longer linker that separates this residue from the acetal group stabilizes theconjugates. Analogously, Lys-207 promotes the beneficial hydrolysis of the succinimide ring when maleimide reagents are used forconjugation, thus stabilizing the subsequent ADCs by impairing the undesired retro-Michael reactions. This work provides newinsights for the design of novel ADCs with improved stability properties., We thank the Agencia Estatal Investigación of Spain (AEI;
Grants RTI2018-099592-B-C21 to F.C. and RTI2018-099592-
B-C22 to G.J.-O.). This project has received funding from the
European Union’s Horizon 2020 research and innovation
program under the Marie Skłodowska-Curie grant agreement
no. 675007. E.J.-M. thanks Universidad de la Rioja for a
postdoctoral fellowship and Ministerio de Universidades of
Spain for a Beatriz Galindo fellowship (BG20/00103) M.J.M.
thanks Xunta da Galicia (Plan I2C-ED481B 2014/086-0 and
ED481B 2018/007). M.C.-C. thanks Schmidt Science Fellow-
ship program. G.S. thanks MINECO for her F. P. I. fellowship
(PRE2018-085973). C.D.N. and G.J.-O. thank the Agencia
Estatal de Investigacion for the Severo Ochoa Excellence
Accreditation to CIC bioGUNE (SEV-2016-0644). We also
thank AstraZeneca for providing the antibodies used in this
study., Peer reviewed